<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00293085</url>
  </required_header>
  <id_info>
    <org_study_id>CECOG/ NSCLC 2.2.001</org_study_id>
    <nct_id>NCT00293085</nct_id>
  </id_info>
  <brief_title>An Open, Randomized, Multicentre, Phase II Pilot Study</brief_title>
  <official_title>An Open, Randomized, Multicentre, Phase II Pilot Study of Docetaxel and Cisplatin in the Adjuvant Treatment of Non-Small Cell Lung Cancer (NSCLC) Stage I-II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central European Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central European Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate efficacy, safety and quality of life adjuvant&#xD;
      docetaxel-cisplatin chemotherapy versus no adjuvant treatment in patients with completely&#xD;
      resected NSCLC Stage I-II.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open multicentre, centrally randomized, two-arm parallel-group, phase II pilot-study.&#xD;
      Duration of the Treatment : Arm A - will be 4-6 cycles Docetaxel 75mg/m2 and Cisplatin&#xD;
      75mg/m2 on day 1 every 21 days.&#xD;
&#xD;
      Arm B untreated control group - best supportive care. A follow-up check-up examination will&#xD;
      be performed every 3 months for a total of three years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">September 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to compare the effect on disease free survival of adjuvant docetaxel and cisplatin in patients with completely resected stage I-II non-small cell lung cancer versus observation only</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>to determine the impact on overall survival of adjuvant docetaxel and cisplatin.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to characterise and quantitate toxicity related to this treatment regimen.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to compare quality of life of patients on both treatment arms.</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel (Taxotere ) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.&#xD;
Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.&#xD;
Premedication:&#xD;
Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.&#xD;
All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.&#xD;
Hyperhydration Patients will require intravenous hydration according to institutional guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparative arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No chemotherapy will be administered. No specific salvage therapy after progression is defined.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel (Taxotere) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.&#xD;
Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.&#xD;
Premedication:&#xD;
Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.&#xD;
All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.&#xD;
Hyperhydration Patients will require intravenous hydration according to institutional guidelines.</description>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically documented NSCLC stage I-II&#xD;
&#xD;
          -  Complete resection of tumor amd resection margins microscopically tumor free.&#xD;
&#xD;
          -  Surgical procedure: According to necessity for oncology radicality a lobectomy,&#xD;
             bilobectomy or pneumectomy will be performed with either radical mediastinal&#xD;
             lymphadenectomy or complete sampling of all relevant lymph node areas.&#xD;
&#xD;
          -  Randomization within 60 days after surgical required.&#xD;
&#xD;
          -  Initial work-up&#xD;
&#xD;
          -  General Conditions: 19-70 years, WHO performance status 0-2, adequate hematological&#xD;
             function, adequate renal and hepatic function, negative pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  NSCLC stage II-IV, SCLC or alveolar carcinoma&#xD;
&#xD;
          -  Clinical evidence of CNS metastases&#xD;
&#xD;
          -  pregnant and lactating patients&#xD;
&#xD;
          -  past or concurrent history of malignancies other than NSCLC,except for curatively&#xD;
             treated non melanoma of the skin or in situ cervical carcinoma or other curatively&#xD;
             treated cancer with no evidence of disease for at least five years.&#xD;
&#xD;
          -  prior or concurrent antitumor therapy for NSCLC other than surgery.&#xD;
&#xD;
          -  Concomitant participation in clinical studies of non-approved experimental agents or&#xD;
             procedures.&#xD;
&#xD;
          -  major complications after surgery&#xD;
&#xD;
          -  serious concomitant medical conditions&#xD;
&#xD;
          -  psychological,familial, sociological or geographical conditions which do not permit&#xD;
             compliance with the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph C. Zielinski, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univ. Klinik f. Innere Medizin I</affiliation>
  </overall_official>
  <link>
    <url>http://www.cecog.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>February 16, 2006</study_first_submitted>
  <study_first_submitted_qc>February 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2006</study_first_posted>
  <last_update_submitted>June 22, 2011</last_update_submitted>
  <last_update_submitted_qc>June 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Thomas Brodowicz</name_title>
    <organization>CECOG</organization>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

